Register Login

ZYMEWORKS INC. (ZYME)

(19% Negative) ZYMEWORKS INC. (ZYME) Announces Delay in eligible Trials for up to $1 Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Aug. 25, 2026, 2:55 p.m.

    📋 ZYMEWORKS INC. (ZYME) - Clinical Trial Update

    Filing Date: 2026-08-25

    Accepted: 2026-08-25 10:54:11

    Event Type: Clinical Trial Update

    Event Details:

    ZYMEWORKS INC. (ZYME) Announces Clinical Trial Update ZYMEWORKS INC. (ZYME) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: eligible
    • Diseases/Conditions: up to $1
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: FDA
      • targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015
      • targeting novel pathways in areas of significant unmet medical need. Zymeworks’ complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.Cautionary Note Regarding Forward-Looking StatementsThis press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: ZYMEWORKS INC.
    • Ticker Symbol: ZYME

Search

News categories